383 related articles for article (PubMed ID: 25351972)
1. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
Kim G; Barner JC; Rascati K; Richards K
J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
[TBL] [Abstract][Full Text] [Related]
3. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
[TBL] [Abstract][Full Text] [Related]
5. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
[TBL] [Abstract][Full Text] [Related]
6. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
7. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
[TBL] [Abstract][Full Text] [Related]
9. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
10. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
[TBL] [Abstract][Full Text] [Related]
11. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study.
Huang Y; Agarwal SK; Chatterjee S; Chen H; Johnson ML; Aparasu RR
Clin Rheumatol; 2024 Jan; 43(1):103-116. PubMed ID: 37540382
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
[TBL] [Abstract][Full Text] [Related]
13. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
Kawai VK; Grijalva CG; Arbogast PG; Curtis JR; Solomon DH; Delzell E; Chen L; Ouellet-Hellstrom R; Herrinton L; Liu L; Mitchel EF; Stein CM; Griffin MR
Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1415-24. PubMed ID: 22121511
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
[TBL] [Abstract][Full Text] [Related]
15. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
[TBL] [Abstract][Full Text] [Related]
16. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
17. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
[TBL] [Abstract][Full Text] [Related]
19. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
20. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]